BioNTech investors are starting to see a re-vaccination market: Analyst

Daina Graybosch from SVB Leerink discusses the long-term opportunities for BioNTech's stock as the company raises its COVID-19 vaccine output target with Pfizer and as talk of the need for a booster shot draws the market's attention.
Tue, Mar 30 202110:52 PM EDT